Research peptide

Epitalon

Epitalon is often discussed in longevity-oriented peptide content. The page starts as a regulatory watch entry and should be expanded only after source review.

Regulatory watch Last reviewed 2026-06-30 Next review 2026-07-24

Evidence snapshot

Treat longevity claims as high-review claims that need precise sourcing and conservative wording.

Scheduled for FDA advisory committee discussion in July 2026.

Longevity-related content is especially prone to claim inflation.

Needs a post-meeting update before expansion.

Tracked claims

Epitalon is part of the July 2026 FDA peptide discussion queue.

Evidence level: Primary regulatory

Sources: U.S. Food and Drug Administration

Use the regulatory record as the anchor for the initial page.

Sources on this page

Source records are stored in the repo and linked from each claim.

July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting

U.S. Food and Drug Administration · Primary regulatory · 2026-07-23 · accessed 2026-06-30

FDA advisory committee meeting notice listing multiple peptide bulk substances scheduled for discussion.

Certain bulk drug substances for use in compounding may present significant safety risks

U.S. Food and Drug Administration · Primary regulatory · 2026-01-01 · accessed 2026-06-30

FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.